Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.61 |
| ▸ | DHFR | P00374 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | PAK4 | O96013 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | LTK | P29376 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3772517 | 0.92 | PTGDR2 (0.66) | PTGDR2DHFRKMT2AMAPTALDH1A1 | |
| SCHEMBL3782624 | 0.91 | PTGDR2 (0.63) | PTGDR2DHFRKMT2AMAPTALDH1A1 | |
| SCHEMBL534038 | 0.91 | PTGDR2 (0.72) | PTGDR2DHFRKMT2AGHSRMAOA | |
| SCHEMBL534136 | 0.91 | PTGDR2 (0.62) | PTGDR2DHFRMAPTALDH1A1HTT | |
| SCHEMBL2576482 | 0.91 | PTGDR2 (0.62) | PTGDR2DHFRMAPTALDH1A1 | |
| SCHEMBL2572551 | 0.91 | PTGDR2 (0.62) | PTGDR2KMT2AALDH1A1HTT | |
| SCHEMBL2574634 | 0.89 | PTGDR2 (0.60) | PTGDR2DHFRMAPTALDH1A1 | |
| SCHEMBL3779875 | 0.89 | PTGDR2 (0.58) | PTGDR2KMT2AALDH1A1 | |
| SCHEMBL534884 | 0.88 | PTGDR2 (0.59) | PTGDR2DHFRMAPTALDH1A1HTT | |
| SCHEMBL3779349 | 0.88 | PTGDR2 (0.59) | PTGDR2GHSRHTTMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394830-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| US-20120184579-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2012-07-19 | — | — | US | disclosed |
| US-8173812-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2012-05-08 | — | — | US | disclosed |
| EP-2129661-B1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2012-02-08 | — | — | EP | disclosed |
| EP-2139881-B1 | QUINOLINES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2011-11-09 | — | — | EP | disclosed |
| US-20100144787-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2010-06-10 | — | — | US | disclosed |
| US-20100144786-A1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| EP-2139881-A1 | QUINOLINES AND THEIR THERAPEUTIC USE | Argenta Oral Therapeutics Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| EP-2129661-A1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | Argenta Oral Therapeutics Limited (GB) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008122784-A1 | QUINOLINES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008119917-A1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | ARGENTA DISCOVERY LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144786-A1 | QUINOLINE DERIVATIVES AS CRTH2 RECEPTOR LIGANDS | NR1H2, GPR52, HRH2 | PTGDR2 75/4885DHFR 1926/4885KMT2A 2755/4885 |
| US-20100144787-A1 | Quinolines and Their Therapeutic Use | CHRM3, CHRM2, HRH1 | PTGDR2 301/4885DHFR 919/4885KMT2A 2390/4885 |
| US-20120184579-A1 | Quinolines and Their Therapeutic Use | HRH1, CHRM2, CHRM3 | PTGDR2 316/4885DHFR 930/4885KMT2A 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.